Drugs / Neoantigen Vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06406816 | May 2024 → May 2026 overdue | intrahepatic cholangiocarcinoma | Yongyi Zeng | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT04799431 | May 2023 | colorectal cancer, pancreatic ductal adenocarcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded |
| Phase 1 | NCT04487093 | May 2020 → May 2022 | non-small cell lung carcinoma | First Hospital of Shijiazhuang City | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neoantigen Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06406816 ↗ |
| Modality | Vaccine | “Neoantigen vaccine is a new field of research in tumor immunotherapy” NCT04487093 ↗ |
| Route | Subcutaneous | “Patients received subcutaneous injection of individualized neoantigen peptides vaccine at a dose of 200ug per peptide once a week for 5 weeks.” NCT04487093 ↗ |